N@N

InSite Vision to Hold Annual Meeting of Stockholders in September

^{Published on 2010-05-26 05:35:26 - Market Wire}
 

ALAMEDA, Calif.--([ BUSINESS WIRE ])--InSite Vision Incorporated (OTCBB:INSV), a company developing ophthalmic products for unmet eye care needs, today announced that the companya™s Annual Meeting of Stockholders will be held at 10:00 a.m. Pacific Time on Tuesday, September 28, 2010. The Annual Meeting will be held at the companya™s headquarters at 965 Atlantic Avenue, Alameda, California. InSite Vision plans to mail the definitive proxy statement for the Annual Meeting, as well as its annual report, in mid August.

About InSite Vision

InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. InSite Vision is recognized for the discovery and development of novel ocular pharmaceutical products based on its DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug delivery on the eyea™s surface, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite (azithromycin ophthalmic solution) 1% and Besivancea" (besifloxacin ophthalmic suspension) 0.6%. AzaSite is approved in the United States and Canada and currently marketed by InSite Visiona™s partner, Inspire Pharmaceuticals, in the United States. InSite Vision has formed multiple strategic licensing and distribution agreements with qualified partners to market AzaSite in select countries in Asia and South America upon regulatory approval in those regions. Besivance was approved by the U.S. Food and Drug Administration in 2009 and is being marketed by Bausch & Lomb and Pfizer Inc. InSite Visiona™s product development pipeline also includes ISV-502 and additional product candidates leveraging the companya™s DuraSite platform and ophthalmic drug development expertise. For further information on InSite Vision, please visit [ www.insitevision.com ].